Since insulin icodec has slow and progressive action on the insulin receptors, it has a low potential to increase the likelihood of substantial acute or delayed glucose movement toward cells (about the administration timing) with concomitant inhibition of glucagon and catecholamines, which are the main required conditions for insulin therapy associated hypoglycemia at a normal physical state. This evidence concerns the gene INS and Hypoglycemia.